Delcath Systems Closes Financing and Appoints Dr. Martha Rook as COO

March 20, 2024—Delcath Systems, Inc. an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced the closing of a private placement with certain accredited investors comprised of existing investors, Delcath executives and members of its Board of Directors, for a private placement transaction.

Delcath received gross proceeds from the transaction of approximately $7 million. The company intends to use the net proceeds for working capital purposes and other general corporate purposes.

Additionally, on March 18, the company announced the appointment of Martha S. Rook, PhD, as Chief Operating Officer.

According to Delcath Systems, Dr. Rook is an experienced industry leader with more than 25 years of academic and industry experience in molecular biology, diagnostics development, biologics process development, and biologics manufacturing. She joins Delcath from Insitro where she served as a Chief Technical Operations Officer. Before Insitro, she was with Sigilon Therapeutics, where she served as Chief Technical Operations Officer.

“We are thrilled to welcome Martha, a senior business leader with more than 25 years of experience, to the leadership team,” commented Delcath’s Chief Executive Officer Gerard Michel in the press release. “Her extensive knowledge of the technical, business, and regulatory challenges of supplying complex combination products will be invaluable as we expand the production of Hepzato Kit and Chemosat.”

Delcath Systems advised that its products—Hepzato Kit and Chemosat—are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a percutaneous hepatic perfusion (PHP) procedure. Hepzato kit is Hepzato (melphalan) for injection/hepatic delivery system). Chemosat is a hepatic delivery system for melphalan PHP.